Related Experiment Video
Updated: Aug 2, 2026
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Cytochrome P450 1A1 (CYP1A1) T6325C polymorphism might modulate essential hypertension-associated stroke risk
V Lança1, P Alcântara, J Braz-Nogueira
1Laboratório de Genética, Centro de Metabolismo e Endocrinologia, Faculdade de Medicina de Lisboa, Lisboa, Portugal.
Summary
The cytochrome P450 1A1 (CYP1A1) gene
Area of Science:
- Genetics
- Cardiovascular Disease
- Pharmacogenomics
Background:
- Hypertension is a significant risk factor for stroke.
- Cytochrome P450 1A1 (CYP1A1) influences vasoactive substance production.
- CYP1A1 functional polymorphisms may link to hypertension-related pathologies.
Purpose of the Study:
- Investigate the association between CYP1A1 polymorphisms and stroke in hypertensive patients.
- Determine if CYP1A1 genotype influences essential hypertension risk.
Main Methods:
- Genotyping of 32 hypertension patients for three CYP1A1 polymorphisms.
- Comparison of genotype distributions between hypertensive patients with and without stroke history.
- Analysis of results against a control population (n=152).
Main Results:
- The CYP1A1 T6235C (m1) polymorphism's C allele showed a significant association with stroke (OR = 5.94).
- No association was found between the studied CYP1A1 polymorphism and essential hypertension.
- The C allele was more prevalent in hypertensive patients with a history of stroke.
Conclusions:
- CYP1A1 activity may be related to stroke incidence in essential hypertension patients.
- The studied CYP1A1 polymorphism is linked to stroke, not essential hypertension itself.
- Further research is needed to confirm the role of CYP1A1 in stroke pathogenesis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...